(Q33373033)

English

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

Acute myeloblastic leukemia

1 reference

based on heuristic

inferred from title

16

object named as

S Chevret

1 reference

Europe PubMed Central

26 July 2017

author name string

A-L Taksin

1

1 reference

Europe PubMed Central

26 July 2017

O Legrand

2

1 reference

Europe PubMed Central

26 July 2017

E Raffoux

3

1 reference

Europe PubMed Central

26 July 2017

T de Revel

4

1 reference

Europe PubMed Central

26 July 2017

X Thomas

5

1 reference

Europe PubMed Central

26 July 2017

N Contentin

6

1 reference

Europe PubMed Central

26 July 2017

R Bouabdallah

7

1 reference

Europe PubMed Central

26 July 2017

C Pautas

8

1 reference

Europe PubMed Central

26 July 2017

P Turlure

9

1 reference

Europe PubMed Central

26 July 2017

O Reman

10

1 reference

Europe PubMed Central

26 July 2017

C Gardin

11

1 reference

Europe PubMed Central

26 July 2017

B Varet

12

1 reference

Europe PubMed Central

26 July 2017

S de Botton

13

1 reference

Europe PubMed Central

26 July 2017

F Pousset

14

1 reference

Europe PubMed Central

26 July 2017

H Farhat

15

1 reference

Europe PubMed Central

26 July 2017

H Dombret

17

1 reference

Europe PubMed Central

26 July 2017

S Castaigne

18

1 reference

Europe PubMed Central

26 July 2017

publication date

19 October 2006

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

21

1 reference

Europe PubMed Central

26 July 2017

1

1 reference

Europe PubMed Central

26 July 2017

66-71

1 reference

Europe PubMed Central

26 July 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404434

0 references

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404434

21 January 2018

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404434

21 January 2018

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404434

21 January 2018

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404434

21 January 2018

CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404434

21 January 2018

MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404434

21 January 2018

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404434

21 January 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404434

21 January 2018

JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404434

21 January 2018

Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404434

21 January 2018

Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-gamma1 in acute myeloid leukemia cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404434

21 January 2018

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404434

21 January 2018

Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404434

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2404434

1 reference

Europe PubMed Central

26 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33373033&oldid=1536562486"